ALMS

AI Memo

Alumis

As of 2026-05-23/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-23 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q1 2026 update confirmed strong psoriasis data and extended cash runway • 2026-05-14

Expected move: +50%

Biggest risk

The bear case is that value remains concentrated in a small number of binary TYK2 milestones. Any slip in NDA timing, weaker SLE efficacy, or safety/regulatory friction would pressure the multiple. The company remains loss-making, with Q1 net loss of $93.1 million, so execution and capital allocation still matter [#8-K-2026-05-14].

Invalidation

Break below $14 or thesis failure.

What would change my mind?

The bull case is still centered on envudeucitinib: Phase 3 psoriasis data were strong, the NDA target stays on track for 4Q 2026, and the SLE Phase 2b readout in 3Q 2026 offers a second value-creating shot. Cash of $569.5 million and guidance into Q4 2027 reduce near-term financing pressure, which matters for a late-stage biopharma [#8-K-2026-05-14][#10-Q-2026-05-14].

Research note

Recommendation

—

Confidence

medium

As of

2026-05-23

Base target

$32

p=50%

Bull target

$45

p=30%

Bear target

$14

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

The bull case is still centered on envudeucitinib: Phase 3 psoriasis data were strong, the NDA target stays on track for 4Q 2026, and the SLE Phase 2b readout in 3Q 2026 offers a second value-creating shot.
Cash of $569.5 million and guidance into Q4 2027 reduce near-term financing pressure, which matters for a late-stage biopharma [#8-K-2026-05-14][#10-Q-2026-05-14].
At $22.02, the stock is still well below the packet median target of $38.00, which implies roughly 73% upside.

BearKey bullets

Clinical risk: the SLE Phase 2b topline in 3Q 2026 and longer-term ONWARD3/safety data are the main binary events; any efficacy or tolerability miss would hit the TYK2 thesis.
Financing and operating risk: the company is still loss-making, and although the balance sheet is currently strong, future development still requires substantial capital over time.
Regulatory and execution risk: NDA timing, FDA feedback, CMC/manufacturing issues, or a delay in filing could reset the timeline and the valuation.

WatchKey bullets

Q1 2026 update confirmed strong psoriasis data and extended cash runway

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $32 (p=50%)

Bull/Bear spread: +111% / -34%

Vs latest close: Bull +111% · Base +50% · Bear -34%

Scenario probabilities

Bull Target: $45 (p=30%)Base Target: $32 (p=50%)Bear Target: $14 (p=20%)

Commentary

The May 14 earnings/clinical update was constructive: the company reaffirmed strong psoriasis data, kept the 4Q 2026 NDA target intact, and said cash should fund operations into Q4 2027. Secondary market coverage suggested an initially positive stock reaction, but the move did not fully persist into the May 22 anchor price, and analyst revisions appear mixed rather than uniformly bullish. Because the packet does not include a clean consensus beat/miss table, this should be treated as a catalyst-heavy clinical update rather than a classic earnings re-rating.

As of 2026-05-23 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

The bull case is still centered on envudeucitinib: Phase 3 psoriasis data were strong, the NDA target stays on track for 4Q 2026, and the SLE Phase 2b readout in 3Q 2026 offers a second value-creating shot.
Cash of $569.5 million and guidance into Q4 2027 reduce near-term financing pressure, which matters for a late-stage biopharma [#8-K-2026-05-14][#10-Q-2026-05-14].

Scenarios

Bull Target (Scenario probability)

$45 / p=30% prob

Base Target (Scenario probability)

$32 / p=50% prob

Bear Target (Scenario probability)

$14 / p=20% prob

Price $21 as of 2026-05-27

Nearest Scenario: Bear (∆ 34%)

Targets vs latest close: Bull +111% · Base +50% · Bear -34%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-14
Q1 2026 update confirmed strong psoriasis data and extended cash runway
The May 14 company release reported $93.1 million of net loss, $81.5 million of R&D expense, $569.5 million of cash, cash equivalents and marketable securities, and reiterated that current resources are expected to fund operating and capital requirements into the fourth quarter of 2027 [#8-K-2026-05-14][#10-Q-2026-05-14].
Prob 95.00% • Move 7.00% • Priced-in 80.00%
EVENT2026-09-15
Potentially pivotal SLE Phase 2b topline data in 3Q 2026
The company continues to guide to potentially pivotal Phase 2b topline data for envudeucitinib in systemic lupus erythematosus in 3Q 2026, which is the next major binary de-risking event beyond psoriasis [#8-K-2026-05-14].
Prob 55.00% • Move 25.00% • Priced-in 35.00%
EVENT2026-11-15
Psoriasis NDA submission remains targeted for 4Q 2026
Management said envudeucitinib NDA submission for moderate-to-severe plaque psoriasis remains on track for 4Q 2026 after reporting robust Phase 3 PASI responses and continued improvement through Week 24 [#8-K-2026-05-14].
Prob 70.00% • Move 18.00% • Priced-in 50.00%

Risks

Clinical risk: the SLE Phase 2b topline in 3Q 2026 and longer-term ONWARD3/safety data are the main binary events; any efficacy or tolerability miss would hit the TYK2 thesis.
Financing and operating risk: the company is still loss-making, and although the balance sheet is currently strong, future development still requires substantial capital over time.
Regulatory and execution risk: NDA timing, FDA feedback, CMC/manufacturing issues, or a delay in filing could reset the timeline and the valuation.

Peers

Symbol	Summary
BEAM	Near-cap biotech peer with milestone-driven valuation; useful for gauging how the market prices platform optionality and clinical readouts.
DYN	Same-sector, similar-cap biotech where discrete program updates and financing/runway considerations tend to dominate valuation.
GPCR	Similarly sized biotech peer where investors focus on pipeline execution and catalyst timing more than current earnings power.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-23

AI Stock Memo: ALMS - Alumis - RankAlpha